| Identification | Back Directory | [Name]
FB23-2 | [CAS]
2243736-45-8 | [Synonyms]
FB23-2
FB23-2，1.5g
FB23-2(FTO Demethylase inhibitor FB23-2)
2-[[2,6-Dichloro-4-(3,5-dimethyl-4-isoxazolyl)phenyl]amino]-N-hydroxybenzamide
Benzamide, 2-[[2,6-dichloro-4-(3,5-dimethyl-4-isoxazolyl)phenyl]amino]-N-hydroxy- | [Molecular Formula]
C18H15Cl2N3O3 | [MDL Number]
MFCD32174281 | [MOL File]
2243736-45-8.mol | [Molecular Weight]
392.24 |
| Chemical Properties | Back Directory | [density ]
1.428±0.06 g/cm3(Predicted) | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
DMSO:70.25(Max Conc. mg/mL);179.1(Max Conc. mM) | [form ]
A solid | [pka]
8.72±0.40(Predicted) | [color ]
White to light yellow | [InChI]
1S/C18H15Cl2N3O3/c1-9-16(10(2)26-23-9)11-7-13(19)17(14(20)8-11)21-15-6-4-3-5-12(15)18(24)22-25/h3-8,21,25H,1-2H3,(H,22,24) | [InChIKey]
ILHNIWOZZKIBNW-UHFFFAOYSA-N | [SMILES]
ClC1=C(NC2=C(C(NO)=O)C=CC=C2)C(Cl)=CC(C3=C(C)ON=C3C)=C1 |
| Hazard Information | Back Directory | [Uses]
FB23-2 is a potent and selective inhibitor of mRNA N6-methyladenosine (m6A) demethylase FTO, with an IC50 of 2.6 μM. FB23-2 has anti-proliferation activity. FB23-2 can be used for the research of acute myeloid leukemia (AML)[1]. | [in vivo]
FB23-2 (2 mg/kg; i.p.; daily; for 10 days) substantially suppresses leukemia progression and prolongs survival[1].
FB23-2 exhibits elimination half-life (rat 6.7 h) and Cmax (rat 2421.3 ng/mL) following intraperitoneal injection (rat 3 mg/kg)[1].
| Animal Model: | NOD/LtSz-scid IL2RG-SGM3 (NSGS) mice, xeno-transplanted with MONOMAC6 AML cells[1] | | Dosage: | 2 mg/kg | | Administration: | Intraperitoneal injection, daily, for 10 days | | Result: | Delayed the onset of full-blown leukemic symptoms and significantly prolonged survival by almost doubling the median survival. |
| Animal Model: | Sprague Dawley (SD) rats[1] | | Dosage: | 3 mg/kg (Pharmacokinetic Analysis) | | Administration: | Intraperitoneal injection | | Result: | T1/2 (6.7 hours), Cmax (2421.3 ng/mL). |
| [References]
[1] Huang Y, et al. Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia. Cancer Cell. 2019 Apr 15;35(4):677-691.e10. DOI:10.1016/j.ccell.2019.03.006 |
|
|